Arbutus Biopharma restructures to cut costs & focus on Hepatitis B drug imdusiran. Read more about ABUS stock here.

LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation ...

Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced its financial results for the fourth quarter and fiscal year 2024, ...

Gary Martin makes The Bowerman Watchlist third update announced by The Bowerman Men’s Watch List Committee in conjunction ...

Arbutus Biopharma (NASDAQ:ABUS) stock gains as the company announces a restructuring drive with a 57% workforce reduction.

This weekend, it will be supporters of Trump and Musk who will be hitting the pavement at 700 York Road. A flyer is making ...

In March 2025, the Company’s Board took action to reduce the Company’s workforce by 57% resulting in a total workforce after reductions of 19 ...

Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September 202 ...

*Estimated payments are calculated by Cars.com and are for informational purposes only. We’ve estimated your taxes based on your provided ZIP code. These estimates do not include title ...